Novo Nordisk has multiple weight-loss drugs in various stages of development and approval, according to its R&D pipeline. These include, among others, monlunabant (phase 2); oral and subcutaneous ...

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS ...

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to ...

A thick layer of more than 12 miles of rock may explain why Bermuda seems to float above the surrounding ocean. When you purchase through links on our site, we may earn an affiliate commission. Here’s ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract ...

Lifecore Biomedical, Inc., a an integrated CDMO, and PolyPeptide Laboratories, Inc., a global peptide contract development and manufacturer, entered a collaboration agreement aimed at providing an ...

We report an efficient protocol to synthesize rod-coil diblock copolymers of an α-helical polypeptide and poly(4-vinyl pyridine) via a combination of “living” ring-opening polymerization of α-amino ...

This collaboration offers an integrated solution for customers seeking to outsource the development and manufacturing of microbial and mammalian-expressed peptide drugs, with scalable options that ...